| Patient | Mary McLeod Bethune |
|---|---|
| Date of birth | 1953-07-10 |
| Identifiers | MRN HR-ML043-SYN; SSN (made up) 000-43-2195 |
| Document date | 2026-09-21 |
| Author | Viola Harrington-Mbeki, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subsequent annual wellness visit; no new complaints. [S]
Mrs. Bethune, now 73, returns for her subsequent annual wellness visit, eight weeks after her asthma review. She has had no night waking and uses the reliever inhalation about once a week; her peak flow stays between 320 and 345 L/min. She travelled to Washington twice more for the council's meetings without trouble. She walks on the campus most mornings and has seen the dietitian. Home blood pressure averages 124/74. She completed the health risk assessment beforehand and asked to put her wishes about her care in writing. [S]
| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit, age 73 |
| Active conditions | Asthma, well controlled; hypertensive heart disease without heart failure; hyperlipidemia; chronic rhinosinusitis; reflux, settled; obesity, class 1 |
| Medicines | Budesonide-formoterol with a spacer; fluticasone and saline nasal sprays; amlodipine; atorvastatin |
| Safety events | One asthma exacerbation in June treated at home; no falls or admissions |
| Functional status | Independent in all activities and instrumental activities of daily living |
Health risk assessment. Completed by the patient on paper before the visit and reviewed with her by Dr. Harrington-Mbeki. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, and better than in the spring |
| Psychosocial | Lives alone; family nearby; colleagues and church members visit daily; purposeful work with the council |
| Tobacco and exposures | Never smoked; avoids perfume and dust where she can |
| Alcohol | None (AUDIT-C 0) |
| Physical activity | Walks 20 to 30 minutes on the campus most mornings |
| Nutrition | Seen by the dietitian; less salt; smaller evening meals |
| Activities of daily living | Independent in bathing, dressing, eating, toileting and transfers |
| Instrumental activities of daily living | Manages her medicines, her finances and her travel; a driver takes her to the airport |
| Home safety | Smoke detectors working; grab bar in the bathroom; one loose rug in the hall |
| Hearing and vision | Hears well; glasses for reading; eye examination last year |
| Bladder | Occasional leakage when coughing hard |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight down 2 kg since the spring, intended; energy good |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Negative | Nose clear; no hoarseness or thrush |
| Respiratory | Negative | No night waking; reliever about once a week |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Gastrointestinal | Negative | Heartburn rarely |
| Genitourinary | Positive | Occasional stress leakage with coughing |
| Musculoskeletal | Negative | Mild knee stiffness in the morning; no falls |
| Integumentary | Negative | No rashes or bruising |
| Neurological | Negative | No memory concerns |
| Psychiatric | Negative | Mood good; PHQ-2 0 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two puffs as needed, from an urgent care visit four months ago (used alone, without an inhaled steroid) | Two puffs every 4 hours as needed; she uses it most days | Respiratory tract route | 2025-11-03 to 2026-03-23 | completed | S |
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for five days | 40 mg each morning for five days | Oral route | 2026-06-15 to 2026-06-19 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 2026-03-23 to 2026-06-15 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: two inhalations twice daily and one as needed (stepped up during the exacerbation), no more than 12 inhalations a day | Two inhalations twice daily plus one as needed | Respiratory tract route | 2026-06-15 to 2026-07-27 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: one inhalation twice daily and one as needed, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 2026-07-27 | active | S |
| Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septum | Two sprays each nostril daily | Nasal route | 2026-03-23 | active | S |
| Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid spray | Two sprays each nostril up to four times daily | Nasal route | 2026-03-23 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeks | One capsule daily before breakfast | Oral route | 2026-03-23 to 2026-05-18 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-21 | Body height | 163 | cm | S |
| 2026-09-21 | Body weight | 86 | kg | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 32.4 | kg/m2 | S |
| 2026-09-21 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-09-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-21 | Heart rate | 70 | /min | S |
| 2026-09-21 | Respiratory rate | 16 | /min | S |
| 2026-09-21 | Body temperature | 36.6 | Cel | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-09-21 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-09-21 | Total score [AUDIT-C] | 0 | {score} | S |
Vital signs recorded on 2026-09-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well and upright; weight 86.0 kg, BMI 32.4; blood pressure 126/76, pulse 70 |
| Eyes | Near vision 20/30 with glasses |
| Ears | Whispered-voice test passed on both sides |
| Respiratory | Clear |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Musculoskeletal | Timed Up and Go 11 seconds; rises from a chair without using her arms |
| Neurological | Oriented; Mini-Cog 5 of 5 |
| Psychiatric | Warm, direct and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Wheeze, cough and breathlessness for four months: waking with cough and tight chest two or three nights a week, breathless on one flight of stairs, relieved by albuterol, worse with colds, dust and strong scents; known asthma for many years but never confirmed by lung function testing and never treated with an inhaled steroid. Asthma, COPD and heart failure to be distinguished: spirometry with bronchodilator response, FeNO and an echocardiogram booked | resolved | confirmed | R06.2 | S — Synthetic presenting problem anchored to her documented chronic asthma. Superseded by the diagnosis at the second visit. |
| Blocked nose, thick postnasal drip and a reduced sense of smell for years, worse in the last year; no nosebleeds; never seen by an ear, nose and throat specialist | resolved | confirmed | R09.81 | S — Synthetic upper-airway symptoms; superseded by the diagnosis of chronic rhinosinusitis after nasal endoscopy. |
| Gastro-esophageal reflux: heartburn and an acid taste two or three evenings a week, worse after late meals and lying down; no trouble swallowing, vomiting, black stools or weight loss | active | confirmed | K21.9 | S — Synthetic comorbidity of asthma; not a claim about her real health. |
| Obesity, class 1 (BMI 33.1); she wants to walk more and to keep up with her work, and agreed to talk about it | active | confirmed | E66.811 | S — Synthetic comorbidity recorded in her words and with her agreement; not a claim about her real weight. |
| Moderate asthma exacerbation triggered by a cold: two days of worsening wheeze and night waking despite eight reliever inhalations a day, peak flow 205 L/min (60 percent of her best), oxygen saturation 94 percent; improved to 275 L/min in clinic; treated without admission; resolved | resolved | confirmed | J45.41 | S — Synthetic exacerbation; not a claim about a real attack. |
| Asthma, confirmed: variable airflow obstruction (FEV1 64 percent predicted, rising 270 mL or 21 percent after bronchodilator, with a normal post-bronchodilator FEV1/FVC of 0.72 and normal DLCO); type 2 inflammation (FeNO 46 ppb, blood eosinophils 0.42 x10^3/uL, total IgE 210, house dust mite sensitization); not COPD and not heart failure. Uncontrolled at diagnosis on albuterol alone | active | confirmed | J45.40 | S — Synthetic modern confirmation linked to her documented chronic asthma. |
| Hypertensive heart disease without heart failure: clinic blood pressure 152/88 and 146/86, home average 144/84; mild concentric left ventricular hypertrophy with grade 1 diastolic dysfunction and a normal ejection fraction (62 percent); BNP 48 pg/mL | active | confirmed | I11.9 | S — Synthetic finding of the modern work-up; not a claim about her real heart. |
| Hyperlipidemia: LDL cholesterol 144 mg/dL; 10-year ASCVD risk above 20 percent with hypertension | active | confirmed | E78.5 | S — Synthetic cardiovascular risk factor. |
| Chronic rhinosinusitis without nasal polyps: years of congestion, postnasal drip and reduced smell, with mucosal swelling and mucus in both middle meatuses and no polyps on nasal endoscopy | active | confirmed | J32.9 | S — Synthetic upper-airway comorbidity of asthma; not a claim about her real health. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine | Completed today | High-dose vaccine given |
| COVID-19 vaccine | Completed today | This season's vaccine given |
| RSV vaccine | Completed today | Single dose for an adult 60 to 74 at increased risk from asthma |
| Pneumococcal vaccine | Up to date | PCV20 in March |
| Recombinant zoster vaccine | Up to date | Two doses, completed two years ago |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap five years ago |
| Bone density (DXA) | Ordered | Recommended for women 65 and older; none on record; recent oral corticosteroid |
| Breast cancer screening | Ordered | Biennial mammography to age 74; last mammogram two years ago |
| Colorectal cancer screening | Up to date | Normal colonoscopy seven years ago; screening ends at 75 unless she chooses otherwise |
| Cervical cancer screening | Not indicated | Not recommended after 65 with adequate prior screening |
| Lung cancer screening | Not indicated | Never smoker |
| Depression screening | Completed today | PHQ-2 score 0 |
| Alcohol misuse screening | Completed today | AUDIT-C score 0 |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | Timed Up and Go 11 seconds; advice to remove the loose hall rug |
| Blood pressure, cholesterol and diabetes | Up to date | Blood pressure at target; LDL 88 on atorvastatin; A1c 5.9 percent in March, repeat in March |
Immunizations given today: Influenza vaccine, high-dose, this season; COVID-19 mRNA vaccine, this season's formula; Respiratory syncytial virus vaccine, single dose [S]
Guideline basis: Global Strategy for Asthma Management and Prevention, 2025 update (2025); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); Adult Immunization Schedule by Age (2026)
Follow-up: DXA and mammogram booked. Asthma and blood pressure review in five weeks. Next annual wellness visit in one year. [S]
Voluntary advance care planning discussion of about 25 minutes, with her consent. She named a health care surrogate, recorded in the confidential part of the chart and not named here, and completed a Florida designation of health care surrogate and a living will. She wants full treatment for an asthma attack or any illness she could recover from, including a breathing machine for a short time if needed. If she had an illness from which she could not recover and could no longer recognize people or speak for herself, she would not want resuscitation or a breathing machine, and would want comfort care at home, with her family, her colleagues and her church. To be revisited at any change in her health and at least yearly. [S]